Abstract 4208: <i>In situ</i> vaccination of non-small cell lung cancer with CXCL9/10-engineered dendritic cells combined with PD-1 blockade
Raymond J. Lim(University of California, Los Angeles), Steven M. Dubinett(University of California, Los Angeles), William P. Crosson(University of California, Los Angeles), Samantha Man(University of California, Los Angeles), Ramin Salehi‐Rad(University of California, Los Angeles), Jensen Abascal(University of California, Los Angeles), Tejas S. Patel(University of California, Los Angeles), Kostyantyn Krysan(University of California, Los Angeles), Bin Liu(Jilin University), Rui Li(Johns Hopkins University), Linh M. Tran(University of California, Los Angeles), Camelia Dumitras(University of California, Los Angeles)
Cited by 1
Related Papers
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
|Nature Medicine|2010|338
Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo
|The Journal of Immunology|2000|202
COVID-19 Vaccine Decision-making Factors in Racial and Ethnic Minority Communities in Los Angeles, California
|JAMA Network Open|2021|187
CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer
|Cell Reports Medicine|2024|111